Capital Fund Management (CFM)
CRSP icon

Capital Fund Management (CFM)’s CRISPR Therapeutics CRSP Stock Holding History

Capital Fund Management (CFM)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.87M Sell
89,242
-6,528
-7% -$344K 0.02% 927
2026
Q1 		$4.56M Buy
+95,770
New +$5.05M 0.02% 936
2025
Q1 		– Sell
-18,097
Closed -$767K – 2051
2024
Q4 		$712K Sell
18,097
-32,007
-64% -$1.51M ﹤0.01% 1836
2024
Q3 		$2.35M Buy
+50,104
New +$2.54M 0.01% 1361
2024
Q2 		– Sell
-56,114
Closed -$3.25M – 1920
2024
Q1 		$3.82M Sell
56,114
-16,905
-23% -$1.21M 0.01% 1173
2023
Q4 		$4.57M Buy
+73,019
New +$4.04M 0.01% 1129
2023
Q3 		– Sell
-42,026
Closed -$2.17M – 1958
2023
Q2 		$2.36M Buy
42,026
+29,785
+243% +$1.69M 0.01% 1125
2023
Q1 		$554K Sell
12,241
-48,013
-80% -$2.33M ﹤0.01% 1429
2022
Q4 		$2.45M Buy
+60,254
New +$3.2M 0.02% 866
2022
Q3 		– Sell
-104,142
Closed -$7.55M – 1441
2022
Q2 		$6.33M Sell
104,142
-114,730
-52% -$6.74M 0.06% 448
2022
Q1 		$13.7M Buy
218,872
+129,831
+146% +$8.15M 0.11% 261
2021
Q4 		$6.75M Sell
89,041
-36,926
-29% -$3.23M 0.05% 526
2021
Q3 		$14.1M Buy
125,967
+111,461
+768% +$14M 0.1% 267
2021
Q2 		$2.35M Sell
14,506
-6,397
-31% -$778K 0.02% 871
2021
Q1 		$2.55M Buy
+20,903
New +$3.16M 0.03% 667
2020
Q4 		– Sell
-10,858
Closed -$908K – 1323
2020
Q3 		$908K Buy
+10,858
New +$963K 0.01% 901
2020
Q2 		– Sell
-7,035
Closed -$411K – 1126
2020
Q1 		$298K Buy
7,035
+3,565
+103% +$184K ﹤0.01% 1228
2019
Q4 		$211K Buy
+3,470
New +$189K ﹤0.01% 1739
2018
Q4 		– Sell
-34,040
Closed -$1.18M – 1906
2018
Q3 		$1.51M Buy
+34,040
New +$1.78M 0.01% 1228

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s CRSP Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its CRISPR Therapeutics (CRSP) stake by 6.8% in Q2 2026, selling an estimated $344K and leaving 89,242 shares worth $4.87M. The position accounts for 0.02% of the portfolio, ranked #927.

Capital Fund Management (CFM) first reported a position in CRSP in Q3 2018 and has held it in 19 quarters since. The position peaked at $14.1M in Q3 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital Fund Management (CFM) held 89,242 shares of CRISPR Therapeutics worth $4.87M as of Q2 2026.
  • Capital Fund Management (CFM) sold 6,528 CRISPR Therapeutics shares in Q2 2026, an estimated $344K.
  • CRISPR Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #927 holding.
  • Capital Fund Management (CFM) first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 19 quarters since.
  • Capital Fund Management (CFM)'s CRISPR Therapeutics position peaked at $14.1M in Q3 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.